NEW YORK: Renalytix plc (NASDAQ: RNLX) announced the proprietary Renalytix Accelerating Precision medicine In Diabetes (RAPID) biorepository is on track to exceed 4,000 unique patient biospecimens with matching, deidentified electronic health record data in 2022 through the Company’s real world evidence program.
RAPID, in combination with unique contracted access to large medical center patient cohorts, enables KidneyIntelXTM improvements for its bioprognosticTM methodology and therapeutic response monitoring, and supports expanded regulatory and reimbursement initiatives beginning in calendar year 2022. The RAPID biorepository was initiated in 2020 as a key part of the Renalytix real-world evidence clinical study program to accelerate the development of precision medicine products and services.
With over 95% of KidneyIntelX tested patients from multiple real world evidence programs now consenting for their samples and data to be used, Renalytix expects total biospecimen access for this KidneyIntelX precision medicine platform to exceed 30,000 unique patient specimens by calendar year 2024. The KidneyIntelX RAPID biorepository is expected to continue to grow into one of the largest real-world patient biobanks incorporating current and emerging care standards for kidney disease and diabetes, including use of innovative drug treatments such as SGLT2 inhibitors, GLP1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists.
“The RAPID biorepository is an invaluable and unique source of serial patient blood and data that can accelerate product validation and provide actionable insights to help patients suffering with kidney disease and diabetes. For the KidneyIntelX platform, this will allow us to drive the development of successive versions of KidneyIntelX to address important gaps in care,” said Fergus Fleming, Chief Technology Officer, Renalytix. “Together with our many collaborators, we share the vision for a new future for kidney health, where patients and providers have access to tools for ensuring the right treatment for the patients at the right time.”
Recent breakthroughs in therapies, such as SGLT2 inhibitors, GLP1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists, for the treatment of kidney and cardiovascular outcomes have intensified the need for precision medicine solutions such as KidneyIntelX to understand individual patient risk and the prediction of early-stage disease progression.
KidneyIntelX is the only kidney health platform that has received Breakthrough Device Designation from the U.S. Food and Drug Administration. KidneyIntelX has secured provider agreements with more than 30 state Medicaid programs and is also covered under various commercial insurance programs.
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and one out of two people with very low kidney function who are not on dialysis do not know they have CKD.1 Kidney disease is referred to as a “silent killer” because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer.2 Every day, 13 patients in the United States die while waiting for a kidney transplant.3
Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisTM for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease, progression risk assessment. The Company’s lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.
The “Renalytix Accelerating Precision-medicine In Diabetes” cohort comprises of blood, urine and deidentified electronic health record data from subjects enrolled in multiple Real World Evidence studies sponsored by Renalytix across multiple sites. All participants included in the cohort have consented for their samples and data to be used for future research and development.
KidneyIntelX, is a first-of-kind solution that enables early-stage diabetic kidney disease (DKD) progression risk assessment by combining diverse data inputs, including validated blood-based biomarkers and personalized data from the patient’s health record, and employs a proprietary algorithm to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in DKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.